AG-221
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for AG-221, covering 2025-04-11 to 2025-04-11. Get the full timeline:
Most recent: Clinical Trial Update: Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) With an IDH1 and/or IDH2 Mutation [Phase 1]